Krishnan Suma, President of R&D at Krystal Biotech (KRYS), has demonstrated a consistent pattern of selling activity over his tenure, with no recorded purchases of company stock. According to SEC filings, Suma has executed 52 trades—all sales—totaling approximately $33.3 million in value. His most recent transactions, concentrated in early March 2026, included 11 sales of KRYS shares worth between $104,728 and $1.59 million, with the largest single transaction occurring on March 4, 2026, at $1.59 million. These disposals followed earlier activity in late February 2026, where filings indicate multiple stock awards (coded "F") with no accompanying market purchases, suggesting the sales may have involved vested equity.
Suma’s trading history is exclusively tied to Krystal Biotech, with no diversification into other securities. The absence of buy transactions and the repeated monetization of equity—including a $2.33 million sale in December 2025—paint a clear disposition toward reducing his position. While the sales could reflect routine portfolio management, the scale and one-sided nature of the transactions underscore a sustained trend of divestment rather than accumulation. The lack of insider buying during this period leaves no counterbalance to the outflow, distinguishing Suma’s activity from executives who maintain or increase stakes alongside disposals.
AI-assisted summary